This article is more than 5 years old. Information may no longer be current.

Cellular Dynamics granted $1.2 million to develop patient-derived stem cells for AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The National Eye Institute has granted Cellular Dynamics International a $1.2 million contract to manufacture clinically compatible induced pluripotent stem cells and induced pluripotent stem cell-derived human retinal pigment epithelial cells, according to a company press release.

The induced pluripotent stem cells (iPSCs) and iPSC-derived human retinal pigment epithelial (RPE) cells will be derived from patients with dry age-related macular degeneration and used for investigational new drug-enabling studies, according to the release.

If the investigational new drug is approved, researchers will perform the same procedure to generate clinical-grade iPSC-derived RPE tissue for autologous cellular transplantation in patients with AMD.

The intention of the cells, which are a genetic match to the patient, is to reduce the risk of transplant rejection.

There are currently no FDA-approved therapies for dry AMD, according to the release.